SCHEMBL23826656

SCHEMBL23826656

COC(=O)c1ccc(C(F)(F)F)c(N[C@@H](C(F)F)C2CCN(C(=O)OCc3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 1/20 0.45
CYP2C19 P33261 1/20 0.42
RBP4 P02753 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.40
GRIN2B Q13224 4/20 0.39
F13A1 P00488 1/20 0.39
TGM2 P21980 1/20 0.39
TGM1 P22735 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
PPARG P37231 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39
CETP P11597 1/20 0.38
PDE4B Q07343 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23826659 1.00 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL1764080 0.79 RBP4 (0.61) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL23826855 0.78 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL23826284 0.75 RBP4 (0.43) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826287 0.75 RBP4 (0.43) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826365 0.74 RBP4 (0.43) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826360 0.74 RBP4 (0.43) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826698 0.74 RBP4 (0.44) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826178 0.74 RBP4 (0.44) RBP4MEN1KMT2AEPHX2ALDH1A1
SCHEMBL23826174 0.74 RBP4 (0.44) RBP4MEN1KMT2AEPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113302184-A 1,3, 4-oxadiazolinone compounds and drugs 日本新药株式会社 2021-08-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL PIM1, PIM3, PIM2 SMN1; SMN2 4744/4885NPC1 1541/4885RAB9A 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.